{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:11:37Z","timestamp":1787505097362,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T00:00:00Z","timestamp":1556323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Qianjiang talents project in Zhejiang province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00280-019-03846-x","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T11:04:10Z","timestamp":1556363050000},"page":"527-537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models"],"prefix":"10.1007","volume":"84","author":[{"given":"Qi","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-3909","authenticated-orcid":false,"given":"Qingyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,27]]},"reference":[{"issue":"5","key":"3846_CR1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1087057117696795","volume":"22","author":"Y Fang","year":"2017","unstructured":"Fang Y, Eglen RM (2017) Three-dimensional cell cultures in drug discovery and development. SLAS Discov 22(5):456\u2013472. \n                    https:\/\/doi.org\/10.1177\/1087057117696795","journal-title":"SLAS Discov"},{"issue":"2","key":"3846_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00280-004-0842-x","volume":"55","author":"L Huimin","year":"2005","unstructured":"Huimin L, Ming H (2005) Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol 55(2):159\u2013169","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3846_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00280-004-0914-y","volume":"56","author":"B Chantal","year":"2005","unstructured":"Chantal B, J\u00e9rMe G, Michel D, Chantal F, Dominique B, Richard B (2005) Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother Pharmacol 56(2):173\u2013181","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"3846_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc3138","volume":"11","author":"C Ya","year":"2011","unstructured":"Ya C, Depinho RA, Matthias E, Karen V (2011) Cancer research: past, present and future. Nat Rev Cancer 11(10):749\u2013754","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3846_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1021\/mp300595a","volume":"10","author":"CS Shin","year":"2013","unstructured":"Shin CS, Kwak B, Han B, Park K (2013) Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug. Mol Pharm 10(6):2167\u20132175","journal-title":"Mol Pharm"},{"issue":"5","key":"3846_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1023\/A:1015366331634","volume":"19","author":"T Watanabe","year":"2002","unstructured":"Watanabe T, Hasegawa T, Takahashi H, Ishibashi T, Itagaki H, Sugibayashi K (2002) Utility of MTT assay in three-dimensional cultured human skin model as an alternative for draize skin irritation test: approach using diffusion law of irritant in skin and toxicokinetics\u2013toxicodynamics correlation. Pharm Res 19(5):669\u2013675","journal-title":"Pharm Res"},{"issue":"5","key":"3846_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.semcancer.2005.05.002","volume":"15","author":"K Jong Bin","year":"2005","unstructured":"Jong Bin K (2005) Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15(5):365\u2013377","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3846_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1471-2407-10-263","volume":"10","author":"S Krause","year":"2010","unstructured":"Krause S, Maffini MV, Soto AM, Sonnenschein C (2010) The microenvironment determines the breast cancer cells\u2019 phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer 10(1):263\u2013263","journal-title":"BMC Cancer"},{"key":"3846_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4939-3191-0_11","volume":"1379","author":"G Chandraiah","year":"2016","unstructured":"Chandraiah G, Mandip S (2016) AlgiMatrix?-based 3D cell culture system as an in vitro tumor model: an important tool in cancer research. Methods Mol Biol 1379:117\u2013128","journal-title":"Methods Mol Biol"},{"key":"3846_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tiv.2016.10.009","volume":"38","author":"S Chitrangi","year":"2017","unstructured":"Chitrangi S, Nair P, Khanna A (2017) 3D engineered in vitro hepatospheroids for studying drug toxicity and metabolism. Toxicol In Vitro 38:8\u201318. \n                    https:\/\/doi.org\/10.1016\/j.tiv.2016.10.009","journal-title":"Toxicol In Vitro"},{"issue":"3","key":"3846_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jpba.2010.04.009","volume":"53","author":"D Bartusik","year":"2010","unstructured":"Bartusik D, Tomanek B, Siluk D, Kaliszan R (2010) 19F MRI of 3D CEM cells to study the effects of tocopherols and tocotrienols. J Pharm Biomed Anal 53(3):599\u2013602. \n                    https:\/\/doi.org\/10.1016\/j.jpba.2010.04.009","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"3846_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.yexcr.2012.09.012","volume":"319","author":"Kenny Chitcholtan","year":"2013","unstructured":"Chitcholtan Kenny, Sykes Peter H, Asselin Eric, Sophie Evans (2013) Differences in growth properties of endometrial cancer in three; dimensional (3D) culture and 2D cell monolayer. Exp Cell Res 319(1):75\u201387","journal-title":"Exp Cell Res"},{"issue":"1","key":"3846_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1741-7015-2-16","volume":"2","author":"AK Lalloo","year":"2004","unstructured":"Lalloo AK, Luo FR, Guo A, Paranjpe PV, Lee S-H, Vyas V, Rubin E, Sinko PJ (2004) Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Med 2(1):16. \n                    https:\/\/doi.org\/10.1186\/1741-7015-2-16","journal-title":"BMC Med"},{"issue":"6","key":"3846_CR14","first-page":"461","volume":"54","author":"JA Gottlieb","year":"1970","unstructured":"Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54(6):461\u2013470","journal-title":"Cancer Chemother Rep"},{"issue":"8","key":"3846_CR15","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1158\/1535-7163.MCT-18-0028","volume":"17","author":"L Marzi","year":"2018","unstructured":"Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Msa E, Cushman M (2018) Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors. Mol Cancer Ther 17(8):1694\u20131704","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3846_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/1040-8428(96)00201-6","volume":"24","author":"N Masuda","year":"1996","unstructured":"Masuda N, Kudoh S, Fukuoka M (1996) Irinotecan (CPT-11): pharmacology and clinical applications. Crit Rev Oncol Hematol 24(1):3\u201326. \n                    https:\/\/doi.org\/10.1016\/1040-8428(96)00201-6","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"3846_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2009.08.001","volume":"74","author":"D Lorusso","year":"2010","unstructured":"Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di VG, Scambia G (2010) Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 74(3):163\u2013174","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"3846_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/CAD.0b013e3282f5218b","volume":"19","author":"S Biren","year":"2008","unstructured":"Biren S, Murugesan G, Jayeeta D, Ahamed S, Celeste C, Luz Z, Ahamed N, Mecide G, Dale S, Yong L (2008) Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 19(4):411\u2013420","journal-title":"Anticancer Drugs"},{"issue":"9","key":"3846_CR19","doi-asserted-by":"publisher","first-page":"e45571","DOI":"10.1371\/journal.pone.0045571","volume":"7","author":"L Xiang","year":"2012","unstructured":"Xiang L, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F (2012) A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PloS One 7(9):e45571","journal-title":"PloS One"},{"issue":"2","key":"3846_CR20","first-page":"370","volume":"7","author":"F Li","year":"2017","unstructured":"Li F, Ling X, Harris DL, Liao J, Wang Y, Westover D, Jiang G, Xu B, Boland PM, Jin C (2017) Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity? Am J Cancer Res 7(2):370\u2013382","journal-title":"Am J Cancer Res"},{"issue":"10","key":"3846_CR21","first-page":"1765","volume":"7","author":"L Xiang","year":"2015","unstructured":"Xiang L, Xiaojun L, Kai Z, Nicholas S, Joshua P, Fengzhi L (2015) FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am J Transl Res 7(10):1765\u20131781","journal-title":"Am J Transl Res"},{"issue":"1","key":"3846_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","volume":"14","author":"D Westover","year":"2015","unstructured":"Westover D, Ling X, Lam H, Welch J, Jin C, Gongora C, Del Rio M, Wani M, Li F (2015) FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. Mol Cancer 14(1):92. \n                    https:\/\/doi.org\/10.1186\/s12943-015-0362-9","journal-title":"Mol Cancer"},{"issue":"2","key":"3846_CR23","first-page":"139","volume":"5","author":"X Ling","year":"2013","unstructured":"Ling X, Li F (2013) An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res 5(2):139","journal-title":"Am J Transl Res"},{"key":"3846_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejpb.2017.04.004","volume":"117","author":"Z Zhen","year":"2017","unstructured":"Zhen Z, Shen ZL, Zhai S, Xu JL, Hui L, Qin S, Li QY (2017) Transport of curcumin derivatives in Caco-2 cell monolayers. Eur J Pharm Biopharm 117:123\u2013131","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"3846_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12575-017-0056-3","volume":"19","author":"F Piccinini","year":"2017","unstructured":"Piccinini F, Tesei A, Arienti C, Bevilacqua A (2017) Cell counting and viability assessment of 2D and 3D Cell cultures: expected reliability of the Trypan Blue assay. Biol Proced Online 19(1):8","journal-title":"Biol Proced Online"},{"issue":"01","key":"3846_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1142\/S2339547815500028","volume":"3","author":"S Curran","year":"2015","unstructured":"Curran S, Achilli TM, Leary E, Wilks BT, Vantangoli MM, Boekelheide K, Morgan JR (2015) A 3D spheroid system to evaluate inhibitors of the ABCG2 transporter in drug uptake and penetration. Technology 3(01):54\u201363","journal-title":"Technology"},{"issue":"3","key":"3846_CR27","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.foodchem.2013.05.075","volume":"141","author":"QQ Liang","year":"2013","unstructured":"Liang QQ, Li YS (2013) A rapid and accurate method for determining protein content in dairy products based on asynchronous-injection alternating merging zone flow-injection spectrophotometry. Food Chem 141(3):2479\u20132485","journal-title":"Food Chem"},{"issue":"1","key":"3846_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","volume":"148","author":"H Franziska","year":"2010","unstructured":"Franziska H, Heike M, Claudia D, Jonathan W, Wolfgang MK, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148(1):3\u201315","journal-title":"J Biotechnol"},{"issue":"2","key":"3846_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/00000421-200204000-00021","volume":"25","author":"A J\u00e9rMe","year":"2002","unstructured":"J\u00e9rMe A, Jean-Marie T, Marine GG, Jean-Marie G, Didier R, Daniel A, Jean-Louis M, FranOis G (2002) Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 25(2):198","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"3846_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/jjco\/hyt040","volume":"43","author":"S Tomoo","year":"2013","unstructured":"Tomoo S, Jun-Ichi T, Toshitaka F, Koji F, Koji K, Shuji M, Satoshi M, Akihiko G, Narikazu B (2013) risk factors for severe adverse effects and treatment-related deaths in japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 43(5):483\u2013491","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"3846_CR31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.yexcr.2012.03.026","volume":"318","author":"H Karlssona","year":"2012","unstructured":"Karlssona H, Larsson R, Nygren P (2012) Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res 318(13):1577\u20131585","journal-title":"Exp Cell Res"},{"issue":"5\u20136","key":"3846_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.drudis.2012.10.003","volume":"18","author":"S Breslin","year":"2013","unstructured":"Breslin S, O\u2019Driscoll L (2013) Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 18(5\u20136):240\u2013249","journal-title":"Drug Discov Today"},{"issue":"7","key":"3846_CR33","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1021\/mp500002y","volume":"11","author":"TM Achilli","year":"2014","unstructured":"Achilli TM, Mccalla S, Meyer J, Tripathi A, Morgan JR (2014) Multilayer spheroids to quantify drug uptake and diffusion in 3D. Mol Pharm 11(7):2071\u20132081","journal-title":"Mol Pharm"},{"issue":"9","key":"3846_CR34","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1023\/a:1025785505977","volume":"20","author":"SH Jang","year":"2003","unstructured":"Jang SH, Wientjes MG, Lu D, Au JL-S (2003) Drug delivery and transport to solid tumors. Pharm Res 20(9):1337\u20131350. \n                    https:\/\/doi.org\/10.1023\/a:1025785505977","journal-title":"Pharm Res"},{"issue":"1","key":"3846_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jps.22257","volume":"100","author":"NT Elliott","year":"2015","unstructured":"Elliott NT, Yuan F (2015) A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 100(1):59\u201374","journal-title":"J Pharm Sci"},{"issue":"9","key":"3846_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","volume":"13","author":"G Szak\u00e1cs","year":"2008","unstructured":"Szak\u00e1cs G, V\u00e1radi A, \u00d6zvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME\u2013Tox). Drug Discov Today 13(9):379\u2013393","journal-title":"Drug Discov Today"},{"issue":"3","key":"3846_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3124","volume":"9","author":"SM Huang","year":"2010","unstructured":"Huang SM (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215\u2013236","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3846_CR38","first-page":"6287","volume":"8","author":"FF Sun","year":"2015","unstructured":"Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH, Chen SS, Song J, Ye XQ (2015) Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Pathol 8(6):6287","journal-title":"Int J Clin Exp Pathol"},{"issue":"11","key":"3846_CR39","first-page":"4101","volume":"9","author":"G Hans","year":"2003","unstructured":"Hans G, Ramon S, Jaap V, George P, Jonge MJA, De Martin D, Christel VH, Francis S, Rosendo O, Joan PO (2003) Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 9(11):4101\u20134107","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3846_CR40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/01.cad.0000131687.08175.14","volume":"15","author":"P Graziella","year":"2004","unstructured":"Graziella P, Beretta GL, Franco Z (2004) Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 15(6):545","journal-title":"Anticancer Drugs"},{"issue":"4","key":"3846_CR41","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-06-1277","volume":"13","author":"H Min","year":"2007","unstructured":"Min H, Heyong G, Yi C, Hong Z, Yujun C, Xiongwen Z, Zehong M, Hualiang J, Jian Z, Hongwu S (2007) Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 13(4):1298\u20131307","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3846_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ejmech.2014.06.050","volume":"83","author":"G Rodr\u00edguez-Berna","year":"2014","unstructured":"Rodr\u00edguez-Berna G, Mangas-Sanju\u00e1n V, Gonzalez-Alvarez M, Gonzalez-Alvarez I, Garc\u00eda-Gim\u00e9nez JL, Caba\u00f1as MJD, Bermejo M, Corma A (2014) A promising camptothecin derivative: semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem 83(16):366\u2013373","journal-title":"Eur J Med Chem"},{"issue":"8\/9","key":"3846_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1290\/0604027.1","volume":"42","author":"K Smalley","year":"2006","unstructured":"Smalley K, Lioni M, Herlyn M (2006) Life isn\u2019t flat: taking cancer biology to the next dimension. Vitro Cell Dev Biol Anim 42(8\/9):242\u2013247","journal-title":"Vitro Cell Dev Biol Anim"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03846-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:07:56Z","timestamp":1587856076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03846-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,27]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3846"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03846-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,27]]},"assertion":[{"value":"21 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We would like to submit the manuscript entitled \u201cIn vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models\u201d to be considered for publication in \u201cCancer Chemotherapy and Pharmacology\u201d as an original research report. There is no conflict of interest in the submission of this manuscript, and I would like to declare on behalf of my co-authors that the work has not been published before, or under consideration for publication elsewhere in whole or in part. All the authors listed have approved the manuscript enclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}